Medicilon IncMedicilon IncMedicilon IncMedicilon Inc
  • Home
  • About
    • Medicilon Overview
    • Executive Team
    • CEO Message
    • Corporate Culture
    • Company History
    • Honor
  • Services
    • Integrated Projects
      • Antibody-Drug-Antibody (ADC)
      • Preclinical Research Services
      • IND Filing
      • Bio Drug Development
      • Chemical Drug Development
      • Chemical Compound Druggability Assessment
      • Molecular Imaging & Radiochemistry
      • OINDP Development
      • Preclinical Ophthalmic Research Platform
    • Pharmacology Services
      • Cancer Xenograft Models
      • Orthotopic Models
      • Syngeneic Mouse Models
      • Transgenic Mouse Model
      • Humanized Mouse Model (hPBMCEngrafted)
      • PDX Model
      • Digestive System Models
      • Neurological Disorders Models
      • Metabolic Disease Models
      • Inflammation & Immunological Disease Models
      • Other Disease Models
    • Chemistry Services
      • Medicinal Chemistry Services
      • Synthetic Chemistry
      • Process Development Services
      • Analytical Chemistry
    • Drug Formulation
      • Pre Formulation Development
      • Analytical Development
      • Formulation Development Services
      • Generics Consistency Evaluation
      • Research on Quality Control
      • Clinical Trial Material
      • OINDP Development
    • Biology Services
      • Discovery Biology Services
      • Recombinant Protein Services
      • Computational Biology & Molecular Modeling
      • Crystallization & Structural Determination
      • Kinase Services
      • SeMet Media Sales
    • Bioanalytical Services
      • Large Molecule Bioanalysis
      • Small Molecule Bioanalysis
    • Pharmacokinetic Services
      • In Vivo Assays
      • In Vitro Assays
    • Drug Safety Evaluation
      • Inhalation Toxicity Assessment
  • Customer
    • Customer Reviews
    • New Models of Collaboration
    • Intellectual Property Protection
    • Download Center
  • Careers
  • News
    • Medicilon Events
    • Media Coverage
    • Featured Stories
  • Contact

The new anti-tumor weapon PDX model helps the development of new immune cancer drugs

Home Medicilon Events
NextPrevious

The new anti-tumor weapon PDX model helps the development of new immune cancer drugs

By medicilon | Medicilon Events | 30 April, 2020 |

On April 22, 2020, Dr. Chunlin Chen, founder and CEO of Medicilon, delivered a special lecture entitled “Application of Translational Medicine (PDX Model) in the Research and Development of New Immune Cancer Drugs” Run Run Shaw Hospital affiliated to Medical College of Zhejiang University . The medical staff and medical students of the company shared the construction of the PDX mouse model in the context of tumor treatment and how it promotes the development of individualized tumor treatment and how to serve Chinese cancer patients.

Dr. Chunlin Chen, founder and CEO of Medicilon
Dr. Chunlin Chen, founder and CEO of Medicilon

Medicilon now has nearly ten PDX tumor efficacy models such as gastric cancer and colon cancer, and is committed to accurate drug efficacy evaluation. In the future, the company will focus on improving the highly humanized mouse disease model biobank, providing modern precision medicine with animal models that are highly compatible with human disease characteristics, and developing the most ideal humanized mouse model.
In recent years, with the advancement of high-throughput sequencing technology and targeted therapies, tumor diseases have made breakthrough progress in basic research, translational medicine and clinical research, but many traditional and new therapies for tumors have not brought patients Better prognosis, the failure rate of clinical translational research makes the innovation and development of anti-tumor drugs very limited. The human tumor tissue xenograft model (PDX) is a tumor model established on immunodeficient mice directly from tumor tissues of tumor patients. Because it maintains the tissue structure, morphology, and molecular biological characteristics of clinical tumor tissues, it is more and more widely used in preclinical drug efficacy evaluation and identification of potential biomarkers. It has become a major boost in tumor treatment and has become Hot spots of industry research.

About Medicilon

Medicilon (stock code: 688202) is a drug development outsourcing service company (CRO). Founded on February 2, 2004, the company has gone through 16 years and established a company in Shanghai that integrates compound synthesis, compound activity screening, structural biology, pharmacodynamic evaluation, pharmacokinetic evaluation, toxicological evaluation, and formulation research A comprehensive technical service platform that conforms to international standards and is integrated with new drug registration, and has been recognized by the international drug management department. Medicipua’s animal laboratory facilities have obtained AAALAC (International Association for Animal Evaluation and Certification) certification and National Medical Products Administration NMPA GLP certification, and have reached the US Food and Drug Administration GLP standard.

Medicilon has a rich of experience in global cooperation. Since 2015, Medicilon has served more than 500 active customers worldwide. It has served many global pharmaceutical companies such as Takeda Pharmaceuticals, Johnson & Johnson Pharmaceuticals, GlaxoSmithKline, Roche Pharmaceuticals, etc. R&D outsourcing services are provided by well-known domestic and foreign customers such as Swiss Medicine, Yangzijiang Pharmaceutical, CSPC, Huahai Pharmaceutical, and Zhongsheng Pharmaceutical.

PDX model
NextPrevious

News

  • Medicilon Events
  • Media Coverage
  • Featured Stories

Tags

ADME (12) animal model (3) Animal Models (46) API (3) API process (3) BIAcore 8K (3) bioanalytical testing (3) consistency evaluation (7) COVID-19 (3) CRO (13) CRO company (8) CRO industry (6) diabetes treatment (3) Drug Discovery (8) Drug Safety Evaluation (3) Elisa Assay (4) Formulation Research (3) GLP (3) green chemistry (3) hERG Assay (3) IND Application (3) IND Filing (5) IPO (3) LC-MS (4) Ligand Binding Assay (4) Medicilon (2) Medicilon Inc. (2) neurological disease (4) neurological diseases (4) neurological disorder (5) neurological disorders (4) PDX model (3) Peptide Drugs (3) Pharmacokinetics (9) pharmacokinetics research (6) pk study (2) Preclinical Research (6) PROTAC (4) Protein expression (4) Protein Purification (8) SAPA (5) stability test (2) Synthetic Biology (4) T cell (3) Western Blot Analysis (2)

Top Posts

  • 14 August, 2017

    Factors Affecting Pharmacokinetics of Drugs

  • 14 October, 2016

    Preclinical Drug Development Process

  • 14 February, 2017

    IND Enabling Studies FDA

Share

About Us

  • Medicilon Overview
  • Executive Team
  • CEO Message
  • Company History
  • Corporate Culture
  • Honor

Services

  • Chemistry
  • Biology
  • Bioanalytical
  • Drug Safety Evaluation
  • Formulation Development
  • Pharmacology
  • Pharmacokinetic
  • Integrated Projects

Customer Center

  • Customer Reviews
  • Download Center
  • Intellectual Property Protection
  • New Models of Collaboration

Contact Us

Shanghai Medicilon Inc.

Address: No. 585, Chuanda Road, Pudong, Shanghai, 201200, China
Email: Marketing@medicilon.com
Website: www.medicilon.com

Copyright 2017 Shanghai Medicilon inc. | All Rights Reserved Privacy Policy
  • Languages
  • 中国日本대한민국
  • Home
  • About
    • Medicilon Overview
    • Executive Team
    • CEO Message
    • Corporate Culture
    • Company History
    • Honor
  • Services
    • Integrated Projects
      • Antibody-Drug-Antibody (ADC)
      • Preclinical Research Services
      • IND Filing
      • Bio Drug Development
      • Chemical Drug Development
      • Chemical Compound Druggability Assessment
      • Molecular Imaging & Radiochemistry
      • OINDP Development
      • Preclinical Ophthalmic Research Platform
    • Pharmacology Services
      • Cancer Xenograft Models
      • Orthotopic Models
      • Syngeneic Mouse Models
      • Transgenic Mouse Model
      • Humanized Mouse Model (hPBMCEngrafted)
      • PDX Model
      • Digestive System Models
      • Neurological Disorders Models
      • Metabolic Disease Models
      • Inflammation & Immunological Disease Models
      • Other Disease Models
    • Chemistry Services
      • Medicinal Chemistry Services
      • Synthetic Chemistry
      • Process Development Services
      • Analytical Chemistry
    • Drug Formulation
      • Pre Formulation Development
      • Analytical Development
      • Formulation Development Services
      • Generics Consistency Evaluation
      • Research on Quality Control
      • Clinical Trial Material
      • OINDP Development
    • Biology Services
      • Discovery Biology Services
      • Recombinant Protein Services
      • Computational Biology & Molecular Modeling
      • Crystallization & Structural Determination
      • Kinase Services
      • SeMet Media Sales
    • Bioanalytical Services
      • Large Molecule Bioanalysis
      • Small Molecule Bioanalysis
    • Pharmacokinetic Services
      • In Vivo Assays
      • In Vitro Assays
    • Drug Safety Evaluation
      • Inhalation Toxicity Assessment
  • Customer
    • Customer Reviews
    • New Models of Collaboration
    • Intellectual Property Protection
    • Download Center
  • Careers
  • News
    • Medicilon Events
    • Media Coverage
    • Featured Stories
  • Contact
Medicilon Inc